<DOC>
	<DOCNO>NCT03101280</DOCNO>
	<brief_summary>This Phase Ib , open-label , non-randomized study participant advance gynecological cancer ( Part 1 ) platinum-sensitive ovarian cancer ( Part 2 ) investigate dose , safety , pharmacokinetics , efficacy rucaparib combination atezolizumab . The study conduct 2 part : Dose-Finding Phase ( Part 1 ) Dose-Expansion Phase ( Part 2 ) .</brief_summary>
	<brief_title>A Combination Study Rucaparib Atezolizumab Participants With Solid Tumors Advanced Gynecologic Cancers , With Focus Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Rucaparib</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 A life expectancy least 3 month Have histologically confirm diagnosis gynecological cancer ( ovarian endometrial ) [ Part 1 ] highgrade serous Grade 3 endometrioid epithelial ovarian , fallopian tube , primary peritoneal cancer ( Part 2 ) For Part 1 , receive least one line prior therapy For Part 2 , receive least one two line prior platinumcontaining therapy progress recent platinum therapy platinumsensitive timeframe Have disease measurable defined RECIST v1.1 Have sufficient archival formalinfixed paraffinembedded ( FFPE ) tumor tissue available plan analysis For Part 2 ONLY , CA125 measurement great 2 time upper limit normal ( ULN ) For Part 2 ONLY , disease biopsied For Part 2 ONLY , deleterious germline somatic breast cancer susceptibility gene 1 ( BRCA1 ) BRCA2 mutation tumor wildtype BRCA show high level loss heterozygosity ( LOH ) ( tBRCAwt/LOHhigh ) signature Have adequate organ function History prior malignancy except ) curatively treat nonmelanoma skin cancer , b ) solid tumor treat curatively 3 year ago without evidence recurrence , c ) breast cancer evidence disease inactive least 3 year , ) synchronous endometrial cancer ( Stage 1A ) ovarian cancer Treatment chemotherapy , radiation , hormone ( except corticosteroid megestrol acetate ) , anticancer therapy less equal ( &lt; = ) 14 day prior first dose study treatment Preexisting duodenal stent and/or gastrointestinal disorder defect would , opinion investigator , interfere absorption rucaparib Symptomatic and/or untreated central nervous system metastases Prior treatment poly adenosine diphosphateâˆ’ribose polymerase ( PARP ) inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>